Smith & Nephew PLC Sponsored ADR Stock

$36.21

0.70% today

NYSE, Aug 12, 07:44 pm CET

ISIN

US83175M2052

Symbol

SNN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Smith & Nephew PLC Sponsored ADR Stock price

$35.96

-4.94 12.08% 5Y

NYSE, Closing price Mon, Aug 11 2025

-0.18 0.50%

ISIN

US83175M2052

Symbol

SNN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$15.7b

Enterprise Value

$18.5b

Net debt

$2.8b

Cash

$676.0m

Shares outstanding

876.0m

Valuation (TTM | estimate)

P/E

64.2 | 34.0

P/S

2.6 | 2.5

EV/Sales

3.1 | 3.0

EV/FCF

23.2

P/B

2.8

Dividends

DPS

$0.76

Yield 1Y | 5Y

2.1% | 2.5%

Growth 1Y | 5Y

1.6% | 0.3%

Payout 1Y | 3Y

159.6% | 218.5%

Increased

1 Year

Financials (TTM | estimate)

Revenue

$5.9b | $6.2b

EBITDA

$1.1b | $1.6b

EBIT

$891.0m | $1.1b

Net Income

$491.0m | $927.2m

Free Cash Flow

$797.0m

Growth (TTM | estimate)

Revenue

5.4% | 7.4%

EBITDA

19.9% | 45.3%

EBIT

28.0% | 22.3%

Net Income

61.0% | 125.1%

Free Cash Flow

164.8%

Financial Health

Equity Ratio

50.9%

Return on Equity

7.8%

ROCE

9.7%

ROIC

8.4%

Debt/Equity

0.6

EPS

$0.6

FCF per Share

$0.9

Short interest

0.6%

Employees

17k

Rev per Employee

$330.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Smith & Nephew PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

25 Analysts have issued a Smith & Nephew PLC Sponsored ADR forecast:

13x Buy

52%

11x Hold

44%

More details on Analyst Estimates Including Price Targets

25 Analysts have issued a Smith & Nephew PLC Sponsored ADR forecast:

Buy

52%

Hold

44%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Smith & Nephew PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	5,944 5,944	5% 5% 100%
- Direct Costs	1,781 1,781	2% 2% 30%
Gross Profit	4,163 4,163	7% 7% 70%
- Selling and Administrative Expenses	2,803 2,803	4% 4% 47%
- Research and Development Expense	295 295	5% 5% 5%
EBITDA	1,065 1,065	20% 20% 18%
- Depreciation and Amortization	174 174	9% 9% 3%
EBIT (Operating Income) EBIT	891 891	28% 28% 15%
Net Profit	491 491	61% 61% 8%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Smith & Nephew PLC Sponsored ADR Stock News

Positive

Proactive Investors

●

one day ago

Smith & Nephew: US bank upbeat after meetings with management

Citi has reiterated its buy rating on Smith & Nephew PLC (LSE:SN) following recent meetings with the company's CEO and CFO. The bank highlights a constructive tone around the business despite the decision not to upgrade full-year guidance, citing global uncertainties and tough fourth-quarter comparisons.

Positive

Seeking Alpha

●

5 days ago

Smith & Nephew: Doing Better And Still Offers Value

Smith & Nephew's interim results confirm solid progress, with revenue up 5% and strong cash flow growth, supporting my continued 'buy' rating. Dividend growth has resumed after years of stagnation, and a $500m buyback signals management's confidence in cash generation, though yield remains modest. The company's recovery is gaining traction, even if ambitious margin targets remain unmet; momentu...

Positive

Proactive Investors

●

6 days ago

US bank ‘buy' on Smith & Nephew after better-than-expected results and $500m buyback

Citi has stuck with its ‘buy' call on Smith & Nephew PLC (LSE:SN) after the company delivered quarterly results that were, in Citi's words, “meaningfully better than expected”, and announced a $500mn share buyback that caught many by surprise. In its latest note, it highlighted that Smith & Nephew's organic growth for the second quarter came in “200–250 basis points above Visible Alpha consensu...

More Smith & Nephew PLC Sponsored ADR News

Company Profile

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Deepak Nath
Employees	17,349
Founded	1856
Website	www.smith-nephew.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now